The investigator is testing the addition of venetoclax to 5-azacitidine and vorinostat followed by standard chemotherapy to enhance treatment response in AML patients.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
The investigator is testing the addition of venetoclax to 5-azacitidine and vorinostat followed by standard chemotherapy to enhance treatment response in AML patients.
Venetoclax to Augment Epigenetic Modification and Chemotherapy
-
Children's Wisconsin, Milwaukee, Wisconsin, United States, 53226
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
1 Year to 25 Years
ALL
No
Medical College of Wisconsin,
Michael Burke, MD, STUDY_CHAIR, Medical College of Wisconsin
2027-01